The role of radiotracer imaging in Parkinson disease

Ravina, B.; Eidelberg, D.; Ahlskog, J. E.; Albin, R. L.; Brooks, D. J.; Carbon, M.; Dhawan, V.; Feigin, A.; Fahn, S.; Guttman, M.; Gwinn-Hardy, K.; McFarland, H.; Innis, R.; Katz, R. G.; Kieburtz, K.; Kish, S. J.; Lange, N.; Langston, J. W.; Marek, K.; Morin, L.; Moy, C.; Murphy, D.; Oertel, W. H.; Oliver, G.; Palesch, Y.; Powers, W.; Seibyl, J.; Sethi, K. D.; Shults, C. W.; Sheehy, P.; Stoessl, A. J.; Holloway, R.

doi:10.1212/01.wnl.0000149403.14458.7f

Cited by 374

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

The role of radiotracer imaging in Parkinson disease

Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., Gwinn-Hardy, K., McFarland, H., Innis, R., Katz, R. G., Kieburtz, K., Kish, S. J., Lange, N., Langston, J. W., Marek, K., Morin, L., Moy, C., Murphy, D., Oertel, W. H., Oliver, G., Palesch, Y., Powers, W., Seibyl, J., Sethi, K. D., Shults, C. W., Sheehy, P., Stoessl, A. J., Holloway, R.·2005·Neurology

DOI 10.1212/01.wnl.0000149403.14458.7f

Open this paper in CoChat — free account

Abstract

Radiotracer imaging (RTI) of the nigrostriatal dopaminergic system is a widely used but controversial biomarker in Parkinson disease (PD). Here the authors review the concepts of biomarker development and the evidence to support the use of four radiotracers as biomarkers in PD: [18F]fluorodopa PET, (+)-[11C]dihydrotetrabenazine PET, [123I]beta-CIT SPECT, and [18F]fluorodeoxyglucose PET. Biomarkers used to study disease biology and facilitate drug discovery and early human trials rely on evidence that they are measuring relevant biologic processes. The four tracers fulfill this criterion, although they do not measure the number or density of dopaminergic neurons. Biomarkers used as diagnostic tests, prognostic tools, or surrogate endpoints must not only have biologic relevance but also a strong linkage to the clinical outcome of interest. No radiotracers fulfill these criteria, and current evidence does not support the use of imaging as a diagnostic tool in clinical practice or as a surrogate endpoint in clinical trials. Mechanistic information added by RTI to clinical trials may be difficult to interpret because of uncertainty about the interaction between the interventions and the tracer.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1212/01.wnl.0000149403.14458.7f

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Statistical parametric maps in functional imaging: A general linear approach
Friston, K. J., Holmes, A. P., Worsley, K. J., Poline, J. ‐., Frith, C. D., & Frackowiak, R. S. J. (1994) · Human Brain Mapping · doi:10.1002/hbm.460020402 · Cited by 9,688
Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease
Freed, C. R., Greene, P. E., Breeze, R. E., Tsai, W.-Y., DuMouchel, W., Kao, R., Dillon, S., Winfield, H., Culver, S., Trojanowski, J. Q., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103083441002 · Cited by 2,366
Self-citation
A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa
Rascol, O., Brooks, D. J., Korczyn, A. D., De Deyn, P. P., Clarke, C. E., & Lang, A. E. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005183422004 · Cited by 1,539
Self-citation
Pramipexole vs Levodopa as Initial Treatment for Parkinson Disease: A 4-Year Randomized Controlled Trial
(2004) · Archives of Neurology · doi:10.1001/archneur.61.7.1044 · Cited by 561
Relationships among the metabolic patterns that correlate with mnemonic, visuospatial, and mood symptoms in Parkinson’s disease
Mentis, M. J., McIntosh, A. R., Perrine, K., Dhawan, V., Berlin, B., Feigin, A., Edwards, C., Mattis, P., & Eidelberg, D. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.5.746 · Cited by 136
Self-citation

Show all 6 references

Research works printed but not linked: 55

10.1067/mcp.2001.113989 · DOI · Paper page
10.1016/S0197-2456(01)00153-2 · DOI · Paper page
10.1002/ana.410340306 · DOI
10.1002/ana.410340304 · DOI · Paper page
10.1146/annurev.neuro.20.1.125 · DOI · Paper page
10.1016/0306-4522(95)00167-H · DOI
10.1002/(SICI)1098-2396(20000315)35:4<250::AID-SYN2>3.0.CO;2-S · doi:10.1002/(sici)1098-2396(20000315)35:4<250::aid-syn2>3.0.co;2-s
10.1016/0006-8993(94)90856-7 · DOI
10.1002/mds.10578 · DOI
10.1523/JNEUROSCI.21-17-06853.2001 · DOI · Paper page
10.1002/ana.410350421 · DOI
10.1136/jnnp.65.2.164 · DOI
10.1093/brain/120.8.1315 · DOI
10.1002/mds.870050304 · DOI
10.1212/WNL.57.11.2083 · DOI
10.1126/science.1087753 · DOI · Paper page
10.1136/jnnp.69.3.308 · DOI · Paper page
10.1136/jnnp.66.4.431 · DOI · Paper page
Dahwan V, Ma Y, Pillai V, et al. Comparative analysis of striatal F-DOPA uptake in Parkinson’s disease: ratio method versus graphical approach. J Nucl Med 2002;43:1324–1330.
10.1002/mds.10562 · DOI
10.1002/ana.410380407 · DOI · Paper page
10.1212/WNL.57.11.2089 · DOI · Paper page
10.1002/mds.1139 · DOI
10.1136/jnnp.64.3.314 · DOI · Paper page
10.1093/brain/120.12.2197 · DOI
Moeller JR, Nakamura T, Mentis MJ, et al. Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 1999;40:1264–1269.
10.1002/1531-8249(200004)47:4<493::AID-ANA13>3.0.CO;2-4 · DOI
10.1212/WNL.45.11.1995 · DOI
10.1002/ana.410400609 · DOI · Paper page
10.1001/archneur.1990.00530120034007 · DOI · Paper page
10.1212/WNL.55.10.1540 · DOI
10.1002/1531-8257(200005)15:3<503::AID-MDS1013>3.0.CO;2-V · DOI
10.1002/mds.10482 · DOI
10.1002/ana.410330517 · DOI
10.1002/mds.870130212 · DOI
10.1093/brain/120.12.2187 · DOI
10.1001/archneur.61.8.1224 · DOI
10.1002/ddr.10219 · DOI
Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The result of the Elldopa trial. Neurology 2003;60:A80–A81.
10.1001/jama.284.15.1931 · DOI · Paper page
10.1002/ana.10609 · DOI · Paper page
Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson disease. Arch Neurol 2004;61:1044–1053.
10.1001/jama.287.13.1653 · DOI · Paper page
10.1212/01.WNL.0000044047.58984.2F · DOI
10.1212/01.WNL.0000052681.28286.52 · DOI
10.1016/S0140-6736(02)11668-0 · DOI
10.1002/1531-8257(199905)14:3<436::AID-MDS1008>3.0.CO;2-J · DOI
Nurmi E, Bergman J, Eskola O, et al. Reproducibility and effect of levodopa on dopamine transporter function measurements: a [18F]CFT PET study. Cereb Blood Flow Metab 2000;20:1604–1609.
10.1002/1531-8257(199911)14:6<940::AID-MDS1005>3.0.CO;2-Y · DOI
10.1212/WNL.56.11.1559 · DOI
10.1002/ana.1075 · DOI · Paper page
10.1002/ana.10720 · DOI · Paper page
10.7326/0003-4819-125-7-199610010-00011 · DOI · Paper page
10.1080/00365519709168308 · DOI
10.1212/WNL.58.5.679 · DOI

A double‐blind, placebo‐controlled study to assess the mitochondria‐targeted antioxidant MitoQ as a disease‐modifying therapy in Parkinson's disease
Snow, B. J., Rolfe, F. L., Lockhart, M. M., Frampton, C. M., O'Sullivan, J. D., Fung, V., Smith, R. A. J., Murphy, M. P., Taylor, K. M., & On behalf of the Protect Study Group (2010) · Movement Disorders · doi:10.1002/mds.23148 · Cited by 606
Safety and tolerability of intraputaminal delivery of CERE-120 (adeno-associated virus serotype 2–neurturin) to patients with idiopathic Parkinson's disease: an open-label, phase I trial
Marks, W. J., Ostrem, J. L., Verhagen, L., Starr, P. A., Larson, P. S., Bakay, R. A., Taylor, R., Cahn-Weiner, D. A., Stoessl, A. J., Olanow, C. W., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70065-6 · Cited by 596
Self-citation
The first frontier: digital biomarkers for neurodegenerative disorders
Dorsey, E. R., Papapetropoulos, S., Xiong, M., & Kieburtz, K. (2017) · Digital Biomarkers · doi:10.1159/000477383 · Cited by 162
Self-citation
Dopamine transporters, D2 receptors, and glucose metabolism in corticobasal degeneration
Klaffke, S., Kuhn, A. A., Plotkin, M., Amthauer, H., Harnack, D., Felix, R., & Kupsch, A. (2006) · Movement Disorders · doi:10.1002/mds.21004 · Cited by 87
Wearable sensors during drawing tasks to measure the severity of essential tremor
Ali, S. M., Arjunan, S. P., Peters, J., Perju-Dumbrava, L., Ding, C., Eller, M., Raghav, S., Kempster, P., Motin, M. A., Radcliffe, P. J., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-08922-6 · Cited by 35

See all 374

Authors: Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., Gwinn-Hardy, K., McFarland, H., Innis, R., Katz, R. G., Kieburtz, K., Kish, S. J., Lange, N., Langston, J. W., Marek, K., Morin, L., Moy, C., Murphy, D., Oertel, W. H., Oliver, G., Palesch, Y., Powers, W., Seibyl, J., Sethi, K. D., Shults, C. W., Sheehy, P., Stoessl, A. J., & Holloway, R.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2005-01-25
Volume: 64
Issue: 2
Pages: 208-215
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/01.wnl.0000149403.14458.7f
OpenAlex: W2045716051
Cited by: 374
References: 6
FWCI: 23.60
Type: journal article
Language: en
Open access: closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page: CoChat. (2026). Citation check: The role of radiotracer imaging in Parkinson disease. https://app.cochat.ai/papers/10.1212/01.wnl.0000149403.14458.7f
The paper: Ravina, B., Eidelberg, D., Ahlskog, J. E., Albin, R. L., Brooks, D. J., Carbon, M., Dhawan, V., Feigin, A., Fahn, S., Guttman, M., Gwinn-Hardy, K., McFarland, H., Innis, R., Katz, R. G., Kieburtz, K., Kish, S. J., Lange, N., Langston, J. W., Marek, K., . . . Holloway, R. (2005). The role of radiotracer imaging in Parkinson disease. Neurology. https://doi.org/10.1212/01.wnl.0000149403.14458.7f

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

The role of radiotracer imaging in Parkinson disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Metadata

Record

About these checks

How to cite

Data sources